Is Contrave a GLP-1? The Plain Answer (October 2026)

01 · The short answer

Is Contrave a GLP-1 drug?

No. Contrave is not a GLP-1 drug. Its two ingredients, naltrexone and bupropion, are older medicines that were not developed to copy the gut hormone GLP-1. A GLP-1 medicine is defined by what it does: it activates GLP-1 receptors. Contrave does not do that.

People mix them up because both get described as weight-loss medicines, and both are talked about in the same online communities. Being used for the same goal does not make two medicines the same class.

02 · Side by side

Contrave vs GLP-1: the main differences

The practical point: if you want a GLP-1 type treatment, Contrave will not give you one. If you are comparing the two for another reason, such as a dislike of injections, speak to a prescriber about your full health history first.

Related guides: Glp 1r vs glp 1 and Gliptin and glp 1.

Related guide: Can you take contrave and mounjaro together.

03 · How GLP-1s work

How GLP-1 medicines work

Tirzepatide is the first treatment of its kind to activate two natural gut-hormone receptors at once: GIP and GLP-1. Together these help regulate appetite, slow how quickly the stomach empties, and improve the way the body responds to insulin.¹ In practice, most people feel fuller sooner and less hungry between meals, which supports a reduced-calorie diet.¹³

That dual action is what distinguishes Mounjaro from single-action GLP-1 medicines such as semaglutide. Contrave sits outside this group altogether. For a plain explanation of the terminology, see our guide to GLP-1RA versus GLP-1.

04 · What the trials show

What the trial evidence covers

In the first large head-to-head trial (SURMOUNT-5), adults on tirzepatide lost on average 20.2% of body weight over 72 weeks versus 13.7% on semaglutide 2.4mg (Wegovy).¹⁵ In the STEP 1 trial, adults on semaglutide 2.4mg (Wegovy) lost on average 14.9% of body weight over 68 weeks, compared with 2.4% on placebo.⁹

Both are effective, licensed treatments; which suits you depends on your health profile, tolerance and prescriber advice, not the headline number alone. Individual results vary.

05 · Combining medicines

Contrave and a GLP-1 together

Whether Contrave can be taken with a GLP-1 is a question for a prescriber who knows your full medical history, not something to decide from a web page.

One rule is firm: never run two GLP-1 medicines together. Because Contrave is not a GLP-1, it does not break that rule by itself, but that does not make a combination automatically safe. Tell every prescriber and pharmacist about everything you take.

06 · Better options and alternatives

What are the alternatives to Contrave for weight loss?

No single option suits everyone; a prescriber decides what suits you. There is no tablet form of Mounjaro; tirzepatide is injection-only in the UK.¹ Two GLP-1 weight-loss tablets are now licensed in the UK: Wegovy tablets (oral semaglutide), approved by the MHRA in June 2026, and Foundayo (orforglipron), approved in August 2026. They are different medicines from Mounjaro, with their own dosing, eligibility checks and trial results, and both are prescription-only.²⁰²¹

Orlistat blocks some dietary fat absorption and produces smaller average losses. Wegovy and Saxenda (liraglutide) are other licensed injectables. Supplements sold as a "natural GLP-1", such as berberine, are not medicines, are not regulated for this use and have no comparable trial evidence. For related terms see our pages on Contrave as an appetite suppressant and the comparison of other weight-loss targets with GLP-1.

07 · NHS and private access

NHS and private access to GLP-1 treatment

Mounjaro is available on the NHS, but access is being phased in over several years. NICE recommends it for adults with a BMI of at least 35 plus at least one weight-related condition, and the NHS primary-care rollout began in June 2025 with the highest-need groups first (initially BMI 40+ with four or more qualifying conditions).⁴⁶ Full rollout is expected to take years, which is why many people who meet the licensed criteria choose regulated private treatment rather than waiting.

Mounjaro (tirzepatide) is a prescription-only medicine, supplied only after an online consultation reviewed by a GPhC-registered prescriber. It is used alongside a reduced-calorie diet and increased physical activity. Our free consultation is reviewed by a GPhC-registered prescriber and our supply comes direct from Eli Lilly through LillyDirect. Our GPhC registration is 9012878.